Login to Your Account

DCB-developed cancer drug is cleared for phase I trials in Taiwan

By Dave Silver
Staff Writer

Wednesday, April 30, 2014

TAIPEI, Taiwan – Taiwan's government-funded Development Center for Biotechnology (DCB) said this week that its mTOR inhibitor cancer drug candidate, DCBCI0901, developed in-house and licensed out in 2011 to an alliance of four local pharmaceutical companies, received approval from the FDA and the TFDA to begin phase I trials.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription